3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Central Nervous System Neoplasms
3
Wilms Tumor
2
Sarcoma
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Glioma
2
Ependymoma
2
Xanthogranuloma, Juvenile
1
Sarcoma, Ewing
1
Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion
1
Histiocytic Sarcoma
1
Interventions
Cetuximab
4
Radiosurgery
3
Nivolumab
3
Ipilimumab
3
pembrolizumab
2
Vorinostat
2
N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl-6-(5-((methylsulfonyl)ethyl)aminomethyl)-2-furyl)-4-quinazolinamine
2
Magnetic Resonance Spectroscopy
2
Lapatinib
2
Dasatinib
2
Cisplatin
2
CTLA-4 Antigen
2
Bevacizumab
2
temsirolimus
1
ispinesib
1
eribulin
1
dehydroftorafur
1
apalutamide
1
amivantamab
1
alectinib
1
Specimen Handling
1
Sorafenib
1
Sirolimus
1
Platinum
1
Pilocarpine
1
Pemetrexed
1
Oral Hygiene
1
NVP-BKM120
1
Moxibustion
1
MK 2206
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Has results
×
Salivary Gland Neoplasms
×
larotrectinib
×
Clear all
No trials found.